This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LIFE aTyr Pharma (LIFE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About aTyr Pharma Stock (NASDAQ:LIFE) Get aTyr Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.57▼$2.0752-Week Range N/AVolume269,400 shsAverage Volume514,103 shsMarket Capitalization$131.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Read More Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIFE Stock News HeadlinesMidnight Sun Mining increases 'bought deal' LIFE offering to C$17.5MOctober 3, 2025 | proactiveinvestors.comMidnight Sun Announces Upsize to Previously Announced “Bought Deal†LIFE Offering and Private Placement of Units to C$17.5 MillionOctober 3, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 9 at 2:00 AM | Brownstone Research (Ad)Midnight Sun Mining to raise C$10M in 'bought deal' LIFE offeringOctober 2, 2025 | proactiveinvestors.comEthos Technologies Targets IPO Amid Positive Insurance OfferingsSeptember 30, 2025 | seekingalpha.comDomestic Metals Announces Upsize of LIFE Offering of UnitsSeptember 30, 2025 | globenewswire.comaTyr Pharma Reports Clinical Benefits of Efzofitimod in Phase 3 Study for Pulmonary SarcoidosisSeptember 30, 2025 | quiverquant.comQTABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIASeptember 29, 2025 | prnewswire.comSee More Headlines LIFE Stock Analysis - Frequently Asked Questions How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01. The biotechnology company earned $0.24 million during the quarter, compared to the consensus estimate of $0.11 million. When did aTyr Pharma's stock split? aTyr Pharma's stock reverse split on the morning of Monday, July 1st 2019.The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did aTyr Pharma IPO? aTyr Pharma (LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO). Company Calendar Last Earnings5/02/2024Today10/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:LIFE CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees56Year Founded2005Profitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.39 million Net MarginsN/A Pretax Margin-9,172.11% Return on Equity-56.92% Return on Assets-43.87% Debt Debt-to-Equity Ratio0.02 Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual Sales$350 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares69,010,000Free Float66,458,000Market Cap$131.12 million OptionableOptionable Beta1.19 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:LIFE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.